Securities code: 688289 securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022-006 Sansure Biotech Inc(688289)
Announcement on the progress of increasing shares held by the actual controller and Chairman
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Basic information of share increase plan: Sansure Biotech Inc(688289) (hereinafter referred to as “the company”) disclosed the announcement of Sansure Biotech Inc(688289) on the share increase plan of the actual controller and chairman (Announcement No.: 2021-054) on September 16, 2021. Mr. Dai Lizhong, the actual controller and chairman of the company, plans to, Increase the company’s shares by means allowed by the trading system of Shanghai Stock Exchange (including but not limited to centralized bidding, continuous bidding and block trading), with a total increase of no less than 80 million yuan and no more than 150 million yuan.
Progress in the implementation of the shareholding increase plan: as of January 21, 2022, Mr. Dai Lizhong, the actual controller and chairman of the company, had increased 1584206 shares of the company’s shares, accounting for 0.40% of the company’s total share capital, with a total increase of 80.9883 million yuan. As of the disclosure date of this announcement, the actual increase amount of Mr. Dai Lizhong has reached the lower limit of the stock increase plan. The increase plan has not been implemented yet. Mr. Dai Lizhong will continue to increase the shares of the company within the implementation time of the increase plan in accordance with the relevant increase plan.
There may be a risk that the share increase plan cannot be implemented due to changes in securities market conditions or policy factors.
1、 Basic information of increased holding subjects
(I) name of the increase subject: Mr. Dai Lizhong, actual controller and chairman of the company.
(II) before the disclosure of this share increase plan, Mr. Dai Lizhong directly held 126488642 shares of the company; Meanwhile, it holds 86.96% equity of Hunan Shengwei Investment Management Co., Ltd., and Hunan Shengwei Investment Management Co., Ltd. holds 25132835 shares of the company; It holds 7.08% of the capital contribution of Hunan shengweihuaning Management Consulting Center (limited partnership), and Hunan shengweihuaning Management Consulting Center (limited partnership) holds 4910467 shares of the company; It holds 3.25% of the capital contribution of Hunan Shengwei Dingli Management Consulting Center (limited partnership), and Hunan Shengwei Dingli Management Consulting Center (limited partnership) holds 5112896 shares of the company.
(III) within 12 months before the disclosure of this share increase plan, Mr. Dai Lizhong, the actual controller and chairman of the company, did not disclose the share increase plan.
2、 Main contents of share increase plan
(I) purpose of the proposed increase in shares
Mr. Dai Lizhong, the actual controller and chairman of the company, intends to increase his shares in the company based on his confidence in the future development of the company and his recognition of the long-term investment value of the company.
(II) number or amount of shares to be increased this time
Mr. Dai Lizhong, the actual controller and chairman of the company, plans to increase the total amount of shares not less than 80 million yuan and not more than 150 million yuan.
(III) price of shares to be increased this time
The plan does not set the price range of shares to be increased, and the company’s shares will be increased according to the fluctuation of the company’s stock price and the overall trend of the capital market.
(IV) implementation period of the share increase plan
Considering the market fluctuation, window period, capital arrangement and other factors, in order to ensure the smooth implementation of the share increase plan, the implementation period of the share increase plan is within 12 months from September 16, 2021.
(V) capital arrangement for the proposed increase of shares
Mr. Dai Lizhong, the actual controller and chairman of the company, plans to increase the shares of the company through his own funds or self raised funds.
(VI) mode of the proposed increase in shares
Increase the company’s shares by means allowed by the trading system of Shanghai Stock Exchange (including but not limited to centralized bidding, continuous bidding and block trading).
3、 Uncertainty risk of the implementation of the shareholding increase plan
There may be a risk that the share increase plan cannot be implemented due to changes in securities market conditions or policy factors. In case of relevant risks during the implementation of the shareholding increase plan, the company will timely perform the obligation of information disclosure.
4、 Implementation progress of share increase plan
As of January 21, 2022, Mr. Dai Lizhong, the actual controller and chairman of the company, has increased the company’s shares in total
1584206 shares, accounting for 0.40% of the total share capital of the company, with a total increase of 80.9883 million yuan. As of the disclosure date of this announcement, the actual increase amount of Mr. Dai Lizhong has reached the lower limit of the stock increase plan. The increase plan has not been implemented yet. Mr. Dai Lizhong will continue to increase the shares of the company within the implementation time of the increase plan in accordance with the relevant increase plan.
The changes in the number and proportion of direct shares held by the increased entity before and after the increase are summarized as follows:
Before the increase, after the implementation of the increase plan as of January 21, 2022
Overweight subject
Number of shares (shares) in total share capital proportion of number of shares (shares) in total shares
Dai Lizhong 126488642 31.62% 128072848 32.02%
5、 Other instructions
(I) in the process of implementing the increase plan, the increase subject will comply with the relevant provisions of the CSRC and Shanghai Stock Exchange on the changes in the equity of listed companies and the sensitive period of stock trading.
(II) the company will continue to pay attention to the progress of this shareholding increase plan and fulfill the obligation of information disclosure in time in accordance with the provisions of relevant laws, administrative regulations, departmental rules and normative documents, such as the company law, the securities law, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange, the measures for the administration of the acquisition of listed companies and so on.
It is hereby announced.
Sansure Biotech Inc(688289) board of directors January 22, 2022
